Prospective Grant of Exclusive License: Detection of Infectious Prion Protein by Seeded Conversion of Recombinant Prion Protein

Streszczenie

This is notice, in accordance with 35 U.S.C. 209 and 37 CFR Part 404, that the National Institutes of Health (NIH), Department of Health and Human Services, is contemplating the grant of an exclusive patent license to Amprion, Inc. located in Houston Texas, USA, to practice the inventions embodied in the following Patents and Patent Applications, each entitled "Detection of Infectious Prion Protein by Seeded Conversion of Recombinant Prion Protein": 1. US provisional Application 60/961,364 filed July 20, 2007 [HHS Ref. No. E-109-2007/0-US-01] 2. PCT/US2008/070656, filed July 21, 2008; [HHS Ref. No E-109-2007/ 1-PCT-01] 3. EPC application No 08796382.3 filed July 21, 2008 [HHS Ref. No E-109-2007/1-EP-03] 4. US Application No. 12/177,012, filed July 21, 2008 and issued as US patent 8,216,788 on July 10, 2012 [HHS Ref. No E-109-2007/1-US-02]; 5. US Application No. 13/489,321, filed June 5, 2012 [E-109-2007/1- US-04]; 6. US Application No. 14/263,703, filed April 28, 2014 [E-109-2007/ 1-US-011] The patent rights in these inventions have been assigned to the United States of America. The prospective exclusive licensed territory may be worldwide and the field of use may be limited to in